Overview

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

Status:
Completed

Trial end date:
2020-02-24

Target enrollment:

Participant gender:

Summary

Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.

Phase:

Phase 3

Details

Lead Sponsor:

PharmaMar

Treatments:

Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Topotecan
Vincristine